Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors’ Expert Forum

Overview of attention for article published in Diabetes Care, December 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 3 news outlets
twitter: 123 X users
facebook: 2 Facebook pages

reddit: 1 Redditor
guideline: 5 clinical guideline sources

Readers on

mendeley: 354 Mendeley

So far, Altmetric has seen 145 X posts from 123 X users, with an upper bound of 514,845 followers.

@kidney_boy There was an FDA mandate for cardiovascular outcomes trials before diabetes drug approval. (Since rescinded.) All the Phase III trials had the same, pretty prescriptive, requirements. https://t.co/czlyn9n3so

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum https://t.co/Cf8J6cphp8 https://t.co/TMkWUr1kal

@emilycob @ajnelson The policy giveaway here is such a shame. FDA required CVOT, which found unexpected, important clinical benefits and helped sales for the manufacturers of some good drugs. And then they walk it back. https://t.co/rpjvCGbbVJ

@WesPegden @VPrasadMDMPH @youyanggu @sdbaral For an example of the politics, check this out: https://t.co/rpjvCFTB4b In 2008 FDA req'd new diabetes drugs be grossly noninferior for CV _events_. (Not even CV mortality.) The findings were a huge boon to…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 141 additional X posts.